These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 28786878)
1. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder. Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878 [TBL] [Abstract][Full Text] [Related]
2. Utility of uroplakin II expression as a marker of urothelial carcinoma. Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628 [TBL] [Abstract][Full Text] [Related]
3. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. Ellis CL; Chang AG; Cimino-Mathews A; Argani P; Youssef RF; Kapur P; Montgomery EA; Epstein JI Am J Surg Pathol; 2013 Nov; 37(11):1756-60. PubMed ID: 24061521 [TBL] [Abstract][Full Text] [Related]
4. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510 [TBL] [Abstract][Full Text] [Related]
5. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106 [TBL] [Abstract][Full Text] [Related]
6. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341 [TBL] [Abstract][Full Text] [Related]
7. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030 [TBL] [Abstract][Full Text] [Related]
8. Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions. Leivo MZ; Tacha DE; Hansel DE Hum Pathol; 2021 Jul; 113():28-33. PubMed ID: 33887302 [TBL] [Abstract][Full Text] [Related]
9. Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers. Hui Y; Wang Y; Nam G; Fanion J; Sturtevant A; Lombardo KA; Resnick MB Hum Pathol; 2018 Jul; 77():11-19. PubMed ID: 29317235 [TBL] [Abstract][Full Text] [Related]
10. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435 [TBL] [Abstract][Full Text] [Related]
11. Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. Terada T Int J Clin Exp Pathol; 2013; 6(6):1150-6. PubMed ID: 23696935 [TBL] [Abstract][Full Text] [Related]
12. Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. Klopfer K; Delahunt B; Adamson M; Samaratunga H Anticancer Res; 2014 Nov; 34(11):6779-84. PubMed ID: 25368291 [TBL] [Abstract][Full Text] [Related]
13. [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases]. Zhang W; Jiang YX; Liu Y; Yu WJ; Zhao H; Li YJ Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):433-7. PubMed ID: 24246859 [TBL] [Abstract][Full Text] [Related]
14. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650 [TBL] [Abstract][Full Text] [Related]
15. Metastatic Pleomorphic Lobular Carcinoma of the Breast to the Urinary Bladder: A Report of 10 Cases and Assessment of TRPS1 in the Differential Diagnosis With Plasmacytoid Urothelial Carcinoma. Zhang GN; Susnik B; Paulsen EJ; Lyons LL; Delma KS; Jorda M; Epstein JI; Kryvenko ON Arch Pathol Lab Med; 2024 Oct; 148(10):1110-1118. PubMed ID: 38217332 [TBL] [Abstract][Full Text] [Related]
16. Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites. Tajima S; Koda K Dis Markers; 2016; 2016():2940496. PubMed ID: 27642214 [TBL] [Abstract][Full Text] [Related]
17. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Wendroth SM; Mentrikoski MJ; Wick MR Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392 [TBL] [Abstract][Full Text] [Related]
18. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762 [TBL] [Abstract][Full Text] [Related]
19. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
20. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. O'Connell FP; Wang HH; Odze RD Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]